InvestorRoom D IMMUNE Pharmaceuticals' Oncology Subsidiary, CYTOVIA, Announces Additional Clinical Trial Results on the Efficacy of CepleneĀ® in Combination with Low-Dose IL-2 in Patients With Acute Myeloid Leukemia, Recently Published in Leukemia, a Leading Hematology J Sixty-seven per cent of patients with functional natural killer (NK) cells remained disease-free at a pre-determined end point that followed two years of treatment Wed, 05 Jul 2017 08:30:00 -0400 Immune Pharmaceuticals' Oncology Subsidiary, Cytovia Inc. Provides Update to Proposed Pint Pharma Transaction: Substantial Agreement Reached on Material Terms of the Licensing and Commercialization of CepleneĀ® in Latin America Thu, 29 Jun 2017 08:30:00 -0400 Immune Pharmaceuticals announces initiation of enrollment in clinical trial with CepleneĀ®/ low-dose IL-2 in Chronic Myelomonocytic Leukemia (CMML) Immune's subsidiary, CYTOVIA, to implement development and commercialization plan for Ceplene Tue, 20 Jun 2017 09:14:00 -0400 Immune Receives NASDAQ Compliance Letter Mon, 19 Jun 2017 08:30:00 -0400 Immune Pharmaceuticals Signs Agreement to Regain Worldwide Rights for Ceplene Immune's subsidiary, Cytovia, plans commercialization activities in Europe and Latin America Thu, 15 Jun 2017 09:28:00 -0400